1.Clinical effect of monosialotetrahexosyl ganglioside in the treatment of neonatal intracranial hemorrhage
Tianjun LIU ; Lieping HUANG ; Yanhua LI ; Fei CHEN ; Xiaowei ZOU
Chinese Journal of Primary Medicine and Pharmacy 2020;27(4):428-432
Objective To investigate the clinical effect of monosialotetrahexosyl ganglioside in the treatment of neonatal intracranial hemorrhage.Methods From January 2016 to December 2018,142 neonates with intracranial hemorrhage admitted to the Maternal and Child Health Hospital of Zhoushan were randomly divided into observation group (71 cases) and control group (71 cases) according to the digital table.The control group was treated with routine treatment,while the observation group was treated with ganglioside needle on the basis of the control group.Both two groups were treated for 14 days.The therapeutic effects,muscle tone recovery time,reflex recovery time and consciousness recovery time were compared.The changes of neurobehavioral assessment score (NABA score),TNF-αt,IL-1β,MMP-2,T IMP-1 and NSE levels before and after treatment were compared.Results The total effective rate of the observation group (92.96%) was higher than that of the control group (77.47%) (x2 =6.762,P < 0.05).The recovery time of muscle tension,reflex and consciousness in the observation group [(7.68 ± 1.29) d,(6.83 ± 1.20) d and (8.34 ± 1.54) d] were shorter than those in the control group [(10.25 ± 2.31) d,(9.17 ±1.86) d and (10.53 ± 1.08) d] (t =8.185,8.908,9.811,all P < 0.05).After treatment,the NABA score of the observation group [(40.37 ± 0.65) points] was higher than that of the control group [(37.16 ± 0.93) points] (t =23.838,P < 0.05).The serum levels of TNF-α [(26.37 ± 4.25) pg/L],IL-1β [(16.74 ± 3.24) ng/L],MMP-2 [(78.39 ± 16.57)g/L],TIMP-1 [(179.32 ± 17.65) ng/mL] and NSE [(13.52 ± 2.19) g/L] in the observation group were lower than those in the control group [(53.21 ± 7.39) pg/L,(28.93 ± 5.64) ng/L,(97.42 ±12.63) g/L,(238.63 ± 28) ng/mL and (21.43 ± 2.89) μg/L] (t =26.529,15.792,7.696,14.938,1 8.381,all P < 0.05).Conclusion Ganglioside has good therapeutic effect on neonatal intracranial hemorrhage.It can reduce the serum levels of TNF-α,IL-1β,MMP-2,TIMP-1 and NSE,and improve the neurobehavioral function of neonates.
2.Semi-attached quad-helix appliance can expand the maxillary arches in patients with cleft lip and palate before alveolar bone grafting.
Lieping HUANG ; Ning HUANG ; Xiaoshu DENG ; Xudao CHEN
West China Journal of Stomatology 2012;30(4):393-398
OBJECTIVETo evaluate the clinical effect of semi-attached quad-helix appliance in expanding the narrow maxillary arches in patients with cleft lip and palate.
METHODS15 cases with cleft lip and palate were selected and treated by semi-attached quad-helix appliance. Before, during, and after treatment, the dental arch width between cuspid, the first premolar and first molar were measured.
RESULTSThe upper dental arches of all patients were expanded effectively in about five months. After orthodontic treatment, the upper dental arches were expanded, and the teeth were alined regularly, which provided good conditions for alveolar bone grafting.
CONCLUSIONThe semi-attached quad-helix appliance with the fixed orthodontic treatment can expand the narrow maxillary arches in patients with cleft lip and palate effectively and conveniently.
Alveolar Bone Grafting ; Bicuspid ; Cleft Lip ; Cleft Palate ; Dental Arch ; Humans ; Maxilla ; Molar
3.Profile of gene differential expression in chronic gastritis with deficiency of spleen-QI patients
Weiwen CHEN ; Yingfang WANG ; Shaoxian LAO ; Ruliu LI ; Wenfeng GUO ; Suiping HUANG ; Guixiang WANG ; Qi LUO ; Lieping HUANG ; Jianhua WANG
Chinese Journal of Pathophysiology 1986;0(01):-
AIM:To investigate a profile of gene differential expression in deficiency of spleen-QI syndrome(DSQ)patients.METHODS:4 DSQ patients and 4 healthy volunteers were selected.The gastric mucosa was taken to extract total RNA.The matched samples were hybridized on the gene chip.The fluorescent signals were scanned,the ratio of fluorescent value,the analysis of bioinformatics and t-test were also applied.Related genes were detected by real-time quantitated PCR.RESULTS:Between two groups,54 genes differentially expressed and 72.2% of them were down regulated.45 were genes about metabolism of nutrient substance and immunological regulation,and 71.1% were down regulated.4 had significant difference.Of 5 applied by real-time PCR,4 accorded with the results of the gene chip.CONCLUSION:The differentially expressed genes of DSQ patients are significantly down regulated,especially the genes involved in metabolism of nutrient substance and immunological regulation.
4.Treatment of Murine Allergic Contact Dermatitis with CTLA4-Ig
Qian ZHOU ; Geng KOU ; Weizhu QIAN ; Hao WANG ; Yanjun LIU ; Xiaoyun WANG ; Shuichuan SONG ; Jun JIN ; Xiaodong LI ; Mengchao WU ; Yajun GUO ; Lieping CHEN
Chinese Journal of Dermatology 1995;0(04):-
Objective To study the effects of CTLA4-Ig on mu rine allergic contact dermatitis.Methods Mice were exposed to DNFB to induce allergic contact dermatitis and were i njected with CTLA4-Ig.Ear swelling was measured 24h after antigen challenge.Splenocytes from treated mice were assayed for their ability to prolif erate in response to DNFB or FITC stimulation in vitro.Results Profound inhibition of contact hypersensitivity response(CHS )was shown by 69.7%in mice treated with CTLA4-Ig compared with mice treate d with PBS control.CT-LA4-Ig-treated mice displayed DNFB-specific tolerance,but exhibited a vigorous immune response to FITC when re-sensitizing 14days after the fir st challenge.Adoptive transfer of l ymphocytes from CTLA4-Ig-treated mice could induce inhibition of CHS in recipien t mice.Conclusions CTLA4-Ig can inhibit CHS by blocking B7/CD28co-stimulatory pathway,which provides a new way to suppress typeⅣallergic reaction.[
5.Antitumor immunity elicited by 4-1BBL gene transfected Hepa1-6 in vivo.
Xiaohong LI ; Xiaodong LI ; Jianyong HUANG ; Lixin WEI ; Lieping CHEN ; Mengchao WU ; Yajun GUO
Chinese Journal of Hepatology 2002;10(6):409-412
OBJECTIVETo study the effects of 4-1BBL on antitumor immunity induced in vivo by murine 4-1BBL gene transfected Hepa1-6.
METHODSRetrovirus vector was used to transfer the 4-1BBL gene into syngeneic murine heptocellular carcinoma cell line Hepa1-6. The products were termed as Hepa1-6/4-1BBL, and then the TCV4-1BBL was obtained by treating them with mitomycin (MMC). Three models (immunological model, early model, and later model) were established to study the antitumor effects of TCV4-1BBL.
RESULTS(1)In immunological models, the syngeneic mice were completely protected by inoculation with TCV4-1BBL, survived free from tumor for a long period (over 100 days). (2)In early models (7 days after inoculation), Hepa1-6 tumor cells showed strong immunogenicity effects and (3) In later models (14 days after inoculation), they had obvious antitumor effects and most of the tumors were disappeared.
CONCLUSIONSThe antitumor effect against syngeneic murine hepatocellular carcinoma in vivo is obviously enhanced by treating them with TCV4-1BBL
4-1BB Ligand ; Animals ; Cell Division ; immunology ; Female ; Liver Neoplasms, Experimental ; immunology ; pathology ; prevention & control ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Plasmids ; genetics ; immunology ; Transfection ; Tumor Cells, Cultured ; Tumor Necrosis Factor-alpha ; genetics ; immunology
6.Expressions of protease-activated receptors in human gingival fibroblasts and its functions in periodontitis.
Diya ZHANG ; Lingjing HU ; Shenglai LI ; Lieping SHENG ; Zheng CAO ; Lili CHEN
Chinese Journal of Stomatology 2014;49(1):21-26
OBJECTIVETo investigate the expression types of protease-activated receptors(PAR) in human gingival fibroblasts(HGF) and the functions of PAR in periodontitis.
METHODSPrimary HGF were cultured.Reverse transcription PCR(RT-PCR) was used to detect the expression of PAR in HGF. Recombinant gingipain R (rRgp) was applied to HGF. The change of PAR expression on the cell surface was analyzed by real-time quantitative RT-PCR, and enzyme-linked immunosorbent assay (ELISA) was used to detect the change of the interleukin (IL)-6 production from HGF. The results of RT-PCR and ELISA were statistically analyzed using the two independent samples t-test of SPSS10.0 software.
RESULTSHGF expressed PAR-1 and PAR-3. The expression of PAR-1 and PAR-3 changed after two rRgp treatment with HGF cells. The relative expression of PAR-1 was decreased from 1.04 ± 0.31 to 0.67 ± 0.11 and 0.31 ± 0.11. The relative expression of PAR-3 was decreased from 1.01 ± 0.44 to 0.79 ± 0.13 and 0.44 ± 0.12(P < 0.05). The level of IL-6 was increased after rRgp treatment for 8 h. The control group was (18.77 ± 4.09) µg/L, the rRgp treatment groups were (179.36 ± 15.81) and (320.56 ± 26.19) µg/L respectively.
CONCLUSIONSHGF expressed PAR-1 and PAR-3 and were involved in periodontal inflammation.
Adhesins, Bacterial ; Cell Membrane ; Cysteine Endopeptidases ; Enzyme-Linked Immunosorbent Assay ; Fibroblasts ; Gingiva ; metabolism ; Humans ; Interleukin-6 ; Periodontitis ; metabolism ; Receptors, Proteinase-Activated ; biosynthesis
7. Effects of full-course epidural delivery on puerpera and neonatal
Yiyao HAN ; Lieping HUANG ; Yuxin TANG ; Lanfeng CHEN ; Min BAI
Chinese Journal of Primary Medicine and Pharmacy 2019;26(12):1454-1458
Objective:
To investigate the effects of epidural analgesia on puerpera and neonatal.
Methods:
A total of 150 puerpera were continuously enrolled from May 2017 to May 2018 in Zhoushan Maternal and Child Health Care Hospital, and were divided into analgesia group (102 cases) and non-analgesia group (48 cases) according to their prenatal wishes.The analgesia group was given epidural anesthesia for analgesic delivery, while the control group had no analgesia intervention.Differences in the expression of serum pain and stress hormones were compared between two groups at the time of prenatal, postpartum 1h and 24h.At the same time, differences in neonatal NACS scores were compared between two groups at the time of postpartum 1h, 8h and 24h.
Results:
No statistically significant differences were found between the two groups in prenatal serum pain and stress hormones, but at the time of postpartum 1h and 24h, serum pain media neuropeptide Y (NPY) (
8.Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure.
Fan ZHOU ; Wei WEI ; Chenhui LING ; Lieping GUO ; Haotian SHI ; Lu LI ; Xiaoling CHEN ; Jian HOU
Chinese Journal of Hematology 2015;36(3):186-190
OBJECTIVETo observe treatment response, survival, safety and the improvement of ECOG in patients with refractory multiple myeloma (MM) with serious heart failure after the administration of continuous low-dose of cyclophosphamide combined with prednisone (CP).
METHODSFrom January 2005 to September 2013, a total of 75 patients were treated by metronomic chemotherapy with continuous low-dose cyclophosphamide (50 mg/d) and prednisone (15 mg/d).
RESULTSAmong the 75 patients, 2 were lost for follow-up. In the 73 available patients, the overall response was 64.4%, including 2 patients (2.7%) with complete remission (CR), 4 cases (5.5%) very good partial remission (VGPR), and 24 patients (32.9%) partial remission (PR). The median survival was 12 months (1-70 months) with a median onset time of 90 days (16-120) and a median progressive freedom survival of 12 months (1-60). The level of B-type natriuretic peptide in responders declined significantly, as compared to no responders [(336.6 ± 30.3) ng/L vs (906.4 ± 104.8) ng/L, P<0.01]. Common adverse events were as follows: 32 (43.8%) cases of bone marrow suppression, 26 (35.6%) cases of infection, 8 cases of dizzy as well as sleepiness (11.0%), 7(9.6%) cases of Cushing syndrome, 4 (5.5%) cases of secondary diabetes mellitus, and 3 (4.1%) cases of edema respectively.
CONCLUSIONThe metronomic chemotherapy of cyclophosphamide combined with prednisone had satisfactory impact on the treatment outcome, including the improvement of cardiac functions and physical capacities, better survival and safety in refractory MM with serious heart failure. It provides a novel regimen for such patients.
Antineoplastic Combined Chemotherapy Protocols ; Clinical Protocols ; Cyclophosphamide ; Heart Failure ; Humans ; Multiple Myeloma ; Prednisone ; Remission Induction ; Treatment Outcome